This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/chemspider/
n5http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/chebi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/wikipedia/
n11http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/kegg-compound/
n13http://www.rxlist.com/cgi/generic/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/pubchem-compound/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/pubchem-substance/
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB01149/identifier/national-drug-code-directory/
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01149
rdf:type
n3:Drug
n3:description
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]
n3:dosage
n8:271B4985-363D-11E5-9242-09173F13E4C5 n8:271B4986-363D-11E5-9242-09173F13E4C5 n8:271B4987-363D-11E5-9242-09173F13E4C5 n8:271B4988-363D-11E5-9242-09173F13E4C5 n8:271B4984-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9098663
n3:group
approved withdrawn
n3:halfLife
2-4 hours
n3:indication
For the treatment of depression.
owl:sameAs
n11:DB01149 n18:DB01149
dcterms:title
Nefazodone
adms:identifier
n16:Nefazodone n17:7494 n22:C07256 n23:4294 n24:DB01149 n25:4449 n26:46508323 n27:0087-0031-47 n28:PA450603
n3:mechanismOfAction
Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT<sub>2</sub>) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
n3:packager
n6:271B496F-363D-11E5-9242-09173F13E4C5 n6:271B4970-363D-11E5-9242-09173F13E4C5 n6:271B496D-363D-11E5-9242-09173F13E4C5 n6:271B496E-363D-11E5-9242-09173F13E4C5 n6:271B496B-363D-11E5-9242-09173F13E4C5 n6:271B496C-363D-11E5-9242-09173F13E4C5 n6:271B4977-363D-11E5-9242-09173F13E4C5 n6:271B4978-363D-11E5-9242-09173F13E4C5 n6:271B4975-363D-11E5-9242-09173F13E4C5 n6:271B4976-363D-11E5-9242-09173F13E4C5 n6:271B4973-363D-11E5-9242-09173F13E4C5 n6:271B4974-363D-11E5-9242-09173F13E4C5 n6:271B4971-363D-11E5-9242-09173F13E4C5 n6:271B4972-363D-11E5-9242-09173F13E4C5 n6:271B497D-363D-11E5-9242-09173F13E4C5 n6:271B497B-363D-11E5-9242-09173F13E4C5 n6:271B497C-363D-11E5-9242-09173F13E4C5 n6:271B4979-363D-11E5-9242-09173F13E4C5 n6:271B497A-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Nefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine.
n3:synonym
Nefazodona 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one Nefazodonum Nefazodone
n3:toxicity
Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
n3:volumeOfDistribution
* 0.22 to 0.87 L/kg
n3:foodInteraction
Take this medication either consistently with or without food as instructed by your doctor. Limit garlic, ginger, gingko, and horse chestnut. Avoid avocado. Avoid alcohol.
n3:proteinBinding
Greater than 99% (in vitro, human plasma proteins).
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Nefazodone.htm
n4:hasConcept
n5:M0147142
foaf:page
n13:nefaz.htm n19:nefazodone.html
n3:IUPAC-Name
n7:271B498D-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4993-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4992-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B498F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4990-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4991-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B498B-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4989-363D-11E5-9242-09173F13E4C5 n7:271B49A3-363D-11E5-9242-09173F13E4C5 n7:271B498C-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B498A-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:N06AX06
n3:H-Bond-Acceptor-Count
n7:271B4999-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B499A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4994-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4995-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4997-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4996-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4998-363D-11E5-9242-09173F13E4C5
n3:absorption
Nefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
83366-66-9
n3:category
n3:containedIn
n9:271B4983-363D-11E5-9242-09173F13E4C5 n9:271B4981-363D-11E5-9242-09173F13E4C5 n9:271B4982-363D-11E5-9242-09173F13E4C5 n9:271B497F-363D-11E5-9242-09173F13E4C5 n9:271B4980-363D-11E5-9242-09173F13E4C5 n9:271B497E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B499E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B49A0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B49A1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B49A2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B499D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B499C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B499F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B498E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B499B-363D-11E5-9242-09173F13E4C5